![]() Therefore, manipulating the genome is crucial for elucidating the causes of disease and systematically studying the many genes that underlie intracellular processes. Many human diseases, such as cancer, heart disease, and diabetes, are characterized by multifactorial genetic inheritance ( Khera et al., 2018 Ishigaki et al., 2020). Our data indicate that more suitable mutants can be rapidly generated using CRISPR/Cas9-based techniques to study gene function in Dictyostelium. We demonstrate the use of these tools for some candidate genes. We also describe new tools, including double knockouts using a single CRISPR vector, drug-inducible knockouts, and gene knockdown using CRISPR interference (CRISPRi). Herein, we provide a detailed protocol for the CRISPR/Cas9-based method in Dictyostelium. CRISPR/Cas9 techniques not only provide an alternative to homologous recombination-based gene knockouts but also enable the creation of mutants that were technically unfeasible previously. Recently, we have applied CRISPR/Cas9-mediated approaches in Dictyostelium, allowing the rapid generation of mutants by transiently expressing sgRNA and Cas9 using an all-in-one vector. ![]() In the biomedical model organism Dictyostelium discoideum, the methodology for gene targeting with homologous recombination to generate mutants is well-established. The development of new techniques to create gene knockouts and knock-ins is essential for successful investigation of gene functions and elucidation of the causes of diseases and their associated fundamental cellular processes. 2Laboratory for Cell Signaling Dynamics, RIKEN, Center for Biosystems Dynamics Research (BDR), Osaka, Japan.1Department of Biology, Faculty of Science, Toho University, Funabashi, Japan.Processing over a million specimens each year allows us to provide real-time analytics regarding emerging drug use trends, such as our studies published in JAMA and our most recent Millennium Health Signals Report ™.Kensuke Yamashita 1† Hoshie Iriki 1† Yoichiro Kamimura 2 Tetsuya Muramoto 1* Clinical drug testing is used in various healthcare settings to obtain objective information about patients' recent use of prescription medications and illicit drugs. Walton earned his bachelor's degree from Yale University and a Master of Business Administration degree from the Harvard Business School.Ībout Millennium Health Millennium Health is an accredited specialty laboratory with over a decade of experience delivering timely, accurate, clinically-actionable information through our nationwide medication monitoring and drug testing services. Before leading the esoteric businesses at LabCorp, Walton had numerous roles within the company including heading up strategic planning and mergers and acquisitions and served as the company's Chief Information Officer. Prior to that, he held a number of senior leadership positions at LabCorp, most recently as Executive Vice President of the esoteric testing business and as a member of LabCorp's five-person Executive Committee. Walton was previously CEO at Ameritox and Inform Diagnostics and served as a board member at Oxford Immunotec. I am committed to continuing to support our extraordinarily important mission, as well as the market leading lab testing, customer service, reporting, thought leadership, and compliance that the industry has come to expect from Millennium Health." "I feel very fortunate to be joining Millennium Health at such an exciting time in the Company's history. "Medication monitoring and drug testing are critical in helping address some of society's most pressing health care and public health challenges" said Walton. "With over twenty years of experience working in both public and private clinical diagnostics companies, Scott's expertise in strategic planning, mergers and acquisitions, information technology, and operations will be a great addition to the leadership team already in place at the Company." ![]() "We are very excited to have an executive with such deep industry experience as Scott joining Millennium Health as our new CEO," said Andrew Milgram, Chairman of the Board. 26, 2021 /PRNewswire/ - Millennium Health, a national leader in specialty medication monitoring and drug testing, today announced the appointment of Scott Walton as Chief Executive Officer (CEO) effective immediately. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |